A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Novartis
Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Northwestern University
Cancer Research UK
Latin American Cooperative Oncology Group